The Evidentiary Drift in Oncology: When Regulators Say Yes, and Payers Say Maybe

Bridging the divide between approval and access for oncology therapeutics

Learn more about the difference in evidence standards between payers and regulators, with insights from SSI Strategy.

Discover strategies for closing the gap between the two and learn how a forward-looking approach to trial design can be the key to securing timely approval and access for oncology therapeutics, most notably high-cost, novel modalities.

Download now to learn how:

Oncology drug approval and access are evaluated by different evidence standards
Payers evaluate evidence
Timelines for HTA and EMA are structured in Europe
Small changes in trial design can prevent costly late fixes and accelerate access

To access the insights, please complete the form.

Your Company Email Address

Country *

Opt In?

By completing this form you agree Citeline and SSI Strategy may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and SSI Strategy.